Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05633706 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Jun 6, 2025 → Jun 2027
See other at-risk trials from Nimble Science Ltd.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 6, 2025 to Jun 2027 Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Jun 6, 2025 to Aug 2027
    • Eligibility criteria expanded, about 17 words
    • Site details revised
  2. Enrollment target: 150 to 300v7 Show 6 more changesShow less
    • Primary completion date: Dec 30, 2024 to Jun 6, 2025
    • Study completion date: Jan 1, 2025 to Jun 6, 2025
    • Eligibility criteria expanded, about 138 words
    • Site contact updated
    • Study arms: 6 to 7
    • Collaborators expanded, about 4 words
  3. Site contact updatedv6
  4. Primary completion date: Jun 30, 2023 to Dec 30, 2024
    • Study completion date: Aug 1, 2023 to Jan 1, 2025
    v5
  5. Primary completion date: Mar 31, 2023 to Jun 30, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  2. Start date: Dec 1, 2022 to Jan 9, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Nimble Science Ltd.
7 trials monitored
See 2 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
Crohn's Disease
642 trials monitored
See 34 trials at risk
and 1 more disease
The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means. The study will compare the microbial and metabolomics analysis from the sample collected with the capsule series, to same-participant symptom questionnaires and stool microbial analysis.
Trial Details
NCT Number NCT05633706
Lead Sponsor Nimble Science Ltd.
Collaborators: Mitacs, University of Calgary
Conditions
(from sponsor)		 Irritable Bowel Syndrome, Crohn Disease, Celiac Disease, Ulcerative Colitis, Functional Dyspepsia, Type 2 Diabetes, Healthy
Related terms Celiac Disease, Colitis, Ulcerative, Crohn Disease, Diabetes Mellitus, Type 2, Irritable Bowel Syndrome
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov